Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In reply to Rao et al.

Dose Escalation, Not “New Biology,” Can Account for the Efficacy of Stereotactic Body Radiation Therapy With Non-Small Cell Lung Cancer J. Martin Brown, PhD,* David J. Brenner, PhD,y and David J. Carlson, PhDz *Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California; yCenter for Radiological Research, Columbia University Medical Center, New York, New York; and zDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut